GLYC News and Press, GlycoMimetics Inc. From 06/15/23

Final analysis to be conducted after the earlier of 295 survival events or the FDA-aligned cutoff date; topline results expected by the end of Q2 2024 Prolonged duration of blinded pooled survival in relapsed/refractory Acute Myeloid Leukemia expected to yield clinically mature dataset in Q2 ...

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 7, 2023 at 4:00 p.m. ET. A live webcast of the fireside chat will be available on th...

2023-05-30 08:02:30 ET Summary GlycoMimetics' Phase 3 study of uproleselan for acute myeloid leukemia is expected to continue until early 2024, with the FDA seeking more information on survivability rates. Insider buying and technical momentum indicators suggest a bullish outlook ...

2023-05-24 13:33:04 ET In its preliminary annual 2023 Russell indexes reconstitution, a total of 164 companies will be added and 319 deleted from the Russell microcap index. Following notable healthcare companies will be added and deleted from Russell microcap index: Notable additio...

2023-05-12 10:03:10 ET Gainers: ARS Pharmaceuticals ( SPRY ) +77% . Dermata Therapeutics ( DRMA ) +63% . AirSculpt Technologies ( AIRS ) +27% . GlycoMimetics ( GLYC ) +14% . BioAtla ( BCAB ) +13% . Losers: Heron Thera...

2023-05-10 12:20:38 ET Summary Rarely, a developmental biotech comes along with new chemistry that potentially becomes curative via transplantation. Blood cancers such as AML, MM, and MDS extract a terrible toll on patients and their loved ones. GlycoMimetics may be such a com...

2023-05-03 11:43:09 ET GlycoMimetics, Inc. (GLYC) Q1 2023 Earnings Conference Call May 3, 2023, 8:30 a.m. ET Company Participants Harout Semerjian - CEO Brian Hahn - CFO Edwin Rock - CMO Christian Dinneen-Long - General Counsel Conference Call Participa...

2023-05-03 07:21:55 ET GlycoMimetics press release ( NASDAQ: GLYC ): Q1 GAAP EPS of -$0.17 in-line. As of March 31, 2023, GlycoMimetics had cash and cash equivalents of $65.0 million as compared to $47.9 million as of December 31, 2022. During the quarter the Company raise...

Pivotal Phase 3 study of uproleselan combined with cytarabine-based chemotherapy in relapsed/refractory (R/R) acute myeloid leukemia (AML) continues to be projected to reach final survival event trigger within first half of 2024 Cash and cash equivalents expected to fund current operations in...

GlycoMimetics, Inc. (Nasdaq: GLYC), today announced that it will host a conference call and webcast to report first quarter 2023 financial results on Wednesday, May 3, 2023, at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you will be provided with dia...